Clinical Study Updates, Trial Enrollments, NDA Submissions, Partnerships, and Formation of New Subsidiaries - Research Report on BioMarin, Alnylam, Vertex, Illumina, and Intrexon PR Newswire NEW YORK, October 7, 2013 NEW YORK, October 7, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Illumina, Inc. (NASDAQ: ILMN), and Intrexon Corporation (NYSE: XON). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. BioMarin Pharmaceutical Inc. Research Report On September 29, 2013, BioMarin Pharmaceutical Inc. (BioMarin) provided an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP) inhibitor, BMN 673, for the treatment of solid tumors. According to the presented data, the confirmed RECIST response rate among 14 gBRCA breast cancer patients treated at the dose of 1mg/day selected for the Phase 3 study was 50%, with seven confirmed objective responses - one complete and six partial. Further the data revealed that there were five patients with stable disease lasting at least 24 weeks for an overall clinical benefit response rate at this dose of 86%. In addition, the Company informed that the BMN 673 was generally well-tolerated. Hank Fuchs, M.D., Chief Medical Officer of BioMarin, said, "With the imminent initiation of the Phase 3 program in germline BRCA mutation metastatic breast cancer, we are closer to understanding the significant role BMN 673 may play for patients suffering metastatic breast cancer." The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9b6c_BMRN] -- Alnylam Pharmaceuticals, Inc. Research Report On September 30, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it has completed enrollment in its Phase II trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). According to the recent interim result, ALN-TTR02 has achieved up to 93% knockdown of TTR - the disease-causing protein in ATTR. In addition, the Company also announced that its open-label extension (OLE) study with ALN-TTR02 is open for enrollment. Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam, said "Our ATTR program is the lead effort in our 'Alnylam 5x15' product development and commercialization strategy, which is focused on advancing RNAi therapeutics toward genetically defined targets for the treatment of diseases with high unmet medical need. We are very encouraged with the clinical activity, safety, and tolerability seen to date with ALN-TTR02 in our Phase II multi-dose study performed in ATTR patients, and look forward to sharing further data at the upcoming ISFAP meeting in November." The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5b29_ALNY] -- Vertex Pharmaceuticals Incorporated Research Report On September 30, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA for the approval of KALYDECO™ (ivacaftor) monotherapy for people with cystic fibrosis (CF), six years old and above, who have at least one non-G551D gating mutation in the CF transmembrane conductance regulator (CFTR) gene. According to the Company, currently, KALYDECO is approved for people with CF, six years old and above, who have at least one copy of the G551D mutation. The Company stated that the sNDA submission is based on previously announced data from a Phase 3 study of ivacaftor monotherapy that showed statistically significant improvements in lung function. Vertex also informed that it plans to submit a Marketing Authorization Application (MAA) variation in Europe in October 2013 for people with CF ages six and above, who have at least one non-G551D gating mutation. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e696_VRTX] -- Illumina, Inc. Research Report On September 25, 2013, Illumina, Inc. (Illumina) announced that it has entered into a partnership with Global Genomics Group (G3) to investigate novel biomarkers and biological pathways involved in the development and diagnosis of cardiovascular diseases. According to the agreement, Illumina will conduct whole genome sequencing (WGS) in the GLOBAL (Genetic Loci and the Burden of Atherosclerotic Lesions) clinical study. Szilard Voros, M.D., CEO and Co-Founder of G3, said, "This is the first study of its kind, analyzing trillions of data points from 7,000 patients, designed to investigate the biological basis behind the complex processes responsible for atherosclerosis., To date we have collected more than 2,200 samples, and we anticipate completing enrollment by summer of 2014." The Full Research Report on Illumina, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3cf2_ILMN] -- Intrexon Corporation Research Report On October 2, 2013, Intrexon Corporation (Intrexon) announced the creation of a new Living Arts subsidiary called Biological & Popular Culture, Inc. (BioPop). The Company said that BioPop's team of innovative scientists and creative designers, enabled by the synthetic biology engineering technology of Intrexon, aims to create new bio-diverse products like those found in nature. Andy Bass, CEO of BioPop said, "BioPop aims to evolve the traditional biotechnology industry paradigm that focuses on healthcare and therapeutics. The consumer market is large with diverse interests that will play a vibrant role in biotech's future." Randal J. Kirk, Chairman and CEO of Intrexon added, "While Intrexon continues its work to provide solutions to important problems in Health, Food, Energy and Environment, we created, in partnership with Andy Bass and his team, a separate company to focus on groundbreaking consumer products rooted in synthetic biology. Initial applications will focus on decorative and fine arts - even toys, both of which represent virtually unlimited potential." The Full Research Report on Intrexon Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cb5c_XON] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Clinical Study Updates, Trial Enrollments, NDA Submissions, Partnerships, and Formation of New Subsidiaries - Research Report on
Press spacebar to pause and continue. Press esc to stop.